Sector News

J&J’s consumer health spinoff seeking $3B stock offering in test of IPO market

April 29, 2023
Life sciences

Kenvue’s IPO could boost a stagnant market for initial public offerings in the U.S. The slowdown has been particularly acute among drugmakers, who often account for a substantial share of new listings. Only five biotechs have priced IPOs so far this year, by far the slowest pace to begin any year since 2018, according to data from BioPharma Dive.

Kenvue, which sells brands like Tylenol, Listerine and Band-Aid, is a much larger and more profitable company than the typical company to seek an IPO, especially compared to the early-stage biotechs that typically seek to raise cash via an offering.

Net sales by the division totaled $15 billion in 2022, and just over $3.8 billion over the first three months of this year. Ten brands earned at least $400 million last year. Once a standalone company, Kenvue will employ roughly 22,000 staff across many of the world’s countries. READ MORE

by Ned Pagliarulo


comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach